Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial,
Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
Hanane Yassine, Nathalie De Freitas Caires, Florence Depontieu, Arnaud Scherpereel, Ali Awad, Anne Tsicopoulos, Christophe Leboeuf, Anne Janin, Catherine Duez, Bogdan Grigoriu, Philippe Lassalle
Published Oct 21, 2014 · Vol. 6, No. 5 · pp. 2725-2735
John T. Patton, Mark E. Lustberg, Gerard Lozanski, Sabrina L. Garman, William H. Towns, Callie M. Drohan, Amy Lehman, Xiaoli Zhang, Brad Bolon, Li Pan, A. Douglas Kinghorn, Michael R. Grever, David M. Lucas, Robert A. Baiocchi
Published Jun 12, 2014 · Vol. 6, No. 5 · pp. 2693-2708
John Wrangle, Wei Wang, Alexander Koch, Hariharan Easwaran, Helai P. Mohammad, Xiaoyu Pan, Frank Vendetti, Wim VanCriekinge, Tim DeMeyer, Zhengzong Du, Princy Parsana, Kristen Rodgers, Ray-Whay Yen, Cynthia A. Zahnow, Janis M. Taube, Julie R. Brahmer, Scott S. Tykodi, Keith Easton, Richard D. Carvajal, Peter A. Jones, Peter W. Laird, Daniel J. Weisenberger, Salina Tsai, Rosalyn A. Juergens, Suzanne L. Topalian, Charles M. Rudin, Malcolm V. Brock, Drew Pardoll, Stephen B. Baylin
Published Oct 25, 2013 · Vol. 4, No. 11 · pp. 2067-2079
Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Ruth Bennett, Noujoude Bouguern, Kasper Pedersen, Neil A O’Brien, Ioannis Roxanis, Ji-Liang Li, Esther Bridge, Richard Finn, Dennis Slamon, Patricia McGowan, Michael J. Duffy, Norma O’Donovan, John Crown, Anthony Kong
Published Jul 25, 2013 · Vol. 4, No. 10 · pp. 1592-1605
Keywords: breast cancer, HER2/ErbB2, trastuzumab (Herceptin), neratinib, panHER inhibitor